What are the side effects of BPC-157?

No controlled human study has been published, so no human side effect profile exists. Rodent studies report high tolerability. Any specific list of human side effects is anecdote or extrapolation.

Unknown in humans. Rodent tolerability is high and no lethal dose has been established in that work, but that is short-duration animal data in another species, not a human safety profile.

Does BPC-157 cause cancer?

No study shows that it does, and none excludes it. The reasonable question comes from its mechanism: its repair effects run through angiogenesis, and new blood vessel formation is not selective for the tissue you intend to help.

BPC-157 (Pentadecapeptide)

BPC-157 Side Effects and the Absence of Human Data

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-312 cited sources

No controlled human safety study of BPC-157 has been published, so there is no reported side effect profile in people. Rodent studies describe high tolerability with no established toxic dose, which is a genuine finding and not a substitute for human data. The most substantive concern follows from its own proposed mechanism.

Key facts

Controlled human trials: None published
Rodent tolerability: High; no established LD50
Main theoretical concern: Angiogenesis is non-selective
Long-term data: None in any species at scale
Material quality: A separate risk entirely

The honest answer is an absence

There is no published controlled trial reporting adverse events for BPC-157 in humans. Sites listing a side effect profile are either reporting anecdote or extrapolating from rodent work. Both should be labelled as such, and usually are not. An absence of reported effects is not a safety finding — it reflects that the study which would report them has not been done.

What the animal literature does show

Rodent studies consistently describe high tolerability, and no lethal dose has been established in that work. That is a real result and it is why the compound attracted interest. It also comes from short studies in a different species, at doses and durations chosen for efficacy rather than safety characterisation.

Research material referenced

BPC-157 5mg — third-party HPLC tested

View — £15.99

The concern that follows from the mechanism

BPC-157's studied effects run substantially through angiogenesis — promoting new blood vessel formation, which is how it is proposed to accelerate tissue repair. Angiogenesis is not selective for tissue you want repaired. The theoretical concern is that a systemic pro-angiogenic signal could support any tissue depending on new vasculature, including a tumour. No study has demonstrated this for BPC-157; equally, no study has excluded it, and the mechanism makes it a reasonable question rather than a scare story.

Material is a separate risk from the molecule

Even where a compound is well tolerated, poorly characterised material is not. Synthesis by-products, residual solvents and bacterial endotoxin are risks attaching to the material rather than the sequence, and none of them appears in a headline purity figure.

And this concerns research material

BPC-157 holds no marketing authorisation anywhere. Material supplied for laboratory research is not assessed or supplied for human use, and the rodent findings above do not describe it in that context.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound' — the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it — different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What are the side effects of BPC-157?: No controlled human study has been published, so no human side effect profile exists. Rodent studies report high tolerability. Any specific list of human side effects is anecdote or extrapolation.
Is BPC-157 safe?: Unknown in humans. Rodent tolerability is high and no lethal dose has been established in that work, but that is short-duration animal data in another species, not a human safety profile.
Does BPC-157 cause cancer?: No study shows that it does, and none excludes it. The reasonable question comes from its mechanism: its repair effects run through angiogenesis, and new blood vessel formation is not selective for the tissue you intend to help.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum